Cardiovascular Diseases

Glucosamine Supplement Linked to Lower CVD Risk

A UK prospective cohort study suggested that habitual use of glucosamine supplement to relieve osteoarthritis pain might also be related to lower risks of cardiovascular diseases (CVD) events. The study enrolled 466 039 participants from 2006 to 2010. During a median follow-up of 7 years, there were 10 204 incident CVD events, 3060 CVD deaths, 5745 coronary heart disease events, and 3263 stroke events. After adjustment for age, sex, body mass index, race, lifestyle factors, dietary intakes, drug use, and other supplement use, glucosamine use was associated with a significantly lower risk of total CVD events (hazard ratio 0.85), CVD death (0.78), coronary heart disease (0.82), and stroke (0.91). The findings are in line with several previous studies and suggest that glucosamine might have a preventive role in CVD through anti-inflammatory and mimicking a low carbohydrate diet properties. Source: https://www.bmj.com/

hyangiu

Recent Posts

Function-Guided Complete Revascularization Improves Outcomes in STEMI

In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, complete coronary…

3 hours ago

2026 Fifth Universal Definition of Myocardial Infarction

The Fifth Universal Definition of Myocardial Infarction (MI) updates the classification of MI by defining…

3 hours ago

Updated US Guideline on Pharmacologic Prevention of Migraine in Adults

The US updated evidence-based recommendations provide clinicians with comprehensive guidance on when to initiate pharmacologic…

8 hours ago

Catheter-Directed Thrombolysis Improves Outcomes in Intermediate-High–Risk Pulmonary Embolism

In patients with intermediate-high–risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation significantly reduced…

1 day ago

Atorvastatin Prevents Cardiovascular Events in Older Adults without Prior Cardiovascular Disease

In a large randomized trial, atorvastatin 40 mg daily significantly reduced major cardiovascular events by…

3 days ago

Aficamten Improves Exercise Capacity and Health Status in Nonobstructive HCM

In patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), aficamten significantly improved exercise capacity and patient-reported…

4 days ago

This website uses cookies.